Clinical Trials Logo

Conjunctivitis, Allergic clinical trials

View clinical trials related to Conjunctivitis, Allergic.

Filter by:

NCT ID: NCT00813046 Completed - Clinical trials for Seasonal Allergic Rhinoconjunctivitis

Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis

Start date: December 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether the oral administration of grass pollen peptides to treat allergic rhinitis is safe and well tolerated.

NCT ID: NCT00812799 Active, not recruiting - Clinical trials for Allergic Rhinoconjunctivitis

A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis

Start date: December 2008
Phase: Phase 3
Study type: Interventional

This study will be performed to determine the long-term efficacy of 19.000 BU Oralgen grass pollen administered daily in patients with grass pollen related allergic rhinoconjunctivitis.

NCT ID: NCT00777374 Completed - Clinical trials for Allergic Rhinoconjunctivitis

Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration

ZU-SkinSIT-003
Start date: October 2008
Phase: Phase 2
Study type: Interventional

Seasonal rhinoconjunctivitis or hay fever is a common atopic condition that is frequently seen in clinical practice. Grass pollen is the major cause of pollinosis in many parts of the world. Immunotherapy is the only treatment that may affect the natural course of allergic diseases, and it may also prevent the development of asthma in patients with allergic rhinitis. With conventional subcutaneous desensitization the duration of treatment is around 3-5 years and usually comprises around 30-100 allergen injections. As high allergen doses have to be injected, allergic side effects may occur and patients must stay under medical supervision for at least 1 hour. Transcutaneous immunization (TCI) is a needle -free technique that delivers antigens and adjuvants to potent epicutaneous immune cells. The aim of the new epicutaneous route of desensitization is to more specifically target the immune system by loading Langerhans cells with the allergen. Lower antigen doses can be applied, such that side effects are reduced.

NCT ID: NCT00775658 Completed - Allergic Rhinitis Clinical Trials

Olopatadine Eye Drops and Allergy Skin Testing

Start date: January 2008
Phase: N/A
Study type: Interventional

Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.

NCT ID: NCT00770133 Completed - Clinical trials for Allergic Conjunctivitis

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

Start date: February 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.

NCT ID: NCT00769886 Completed - Clinical trials for Allergic Conjunctivitis

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.

NCT ID: NCT00718744 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The main purpose of the trial is to prove the therapeutic value of the product and enable an effective and safe dosage schedule to be recommended

NCT ID: NCT00689078 Completed - Clinical trials for Allergic Conjunctivitis

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

Start date: May 2008
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy of prednisolone acetate 1% ophthalmic suspension as compared to prednisolone acetate 0.12% ophthalmic suspension, loteprednol etabonate 0.2% ophthalmic suspension, and placebo (Tears Naturale® II) in the prevention of the signs and symptoms of allergic conjunctivitis. Comparisons will be made following 1 week of twice daily (BID) dosing and 1 week of four times daily (QID) dosing.

NCT ID: NCT00655109 Completed - Clinical trials for Conjunctivitis, Allergic

A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

Start date: February 2008
Phase: Phase 4
Study type: Interventional

To compare the clinical efficacy of olopatadine and fluticasone in a 3-week single center, double-masked, randomized, placebo controlled parallel treatment conjunctival allergen challenge (CAC) study in patients with allergic conjunctivitis